Amendment to Annual Report (Form 10-K/A)

This Amendment amends and restates in their entirety Items 10 through 14 of the Original 10-K. Except as described above, this Amendment does not amend, update or change any other items or disclosures in the Original 10-K and does not reflect events occurring after the filing of the Original 10-K. Accordingly, this Amendment should be read in conjunction with the Original 10-K and the Company's other filings made with the SEC subsequent to the filing of the Original 10-K. Defined terms used, but not defined, herein have the meanings ascribed to them in the Original 10-K. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this Amendment also contains new certifications by the Company's principal executive officer and principal financial officer as required by Section 302 of the Sarbanes-Oxley Act of 2002. Item 15(a)(3) of Part IV of the Original 10-K is amended to include the currently dated certifications as exhibits. No financial statements are included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K; accordingly, paragraphs 3, 4 and 5 of the certifications have been omitted. Similarly, because no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted.

On November 12, 2025, the Company (then known as Salarius Pharmaceuticals, Inc.) completed its previously announced merger transaction (the "Merger") with Decoy Therapeutics, Inc. ("Legacy Decoy") pursuant to the Agreement and Plan of Merger, dated as of January 10, 2025, as amended. On January 8, 2026, the Company changed its legal name from "Salarius Pharmaceuticals, Inc." to "Decoy Therapeutics Inc." Except where the context otherwise requires or where otherwise indicated, all historical references to "Salarius" in this Amendment refer to the Company prior to the name change. All share and per share amounts set forth in this Amendment have been adjusted to reflect the 1-for-15 reverse stock split effected on August 15, 2025 and the 1-for-12 reverse stock split effected on March 6, 2026.